US Obesity Rate Declines as Weight Loss Drug Usage Increases
A recent survey conducted by Gallup has revealed a decline in the US adult obesity rate, with a notable decrease from 39.9% in 2022 to 37% in 2025. This statistically significant decrease represents an estimated 7.6 million fewer obese adults over the past three years. The survey, which interviewed 16,946 US adults, defined obesity using the federal standard of having a BMI of 30 or higher.
The report also explored the simultaneous increase in the use of GLP-1 drugs, such as semaglutides like Ozempic and Wegovy, for weight loss. These medications are also used to treat type 2 diabetes, which remains at an all-time high, with 13.8% of Gallup’s Well-Being Index participants reporting a diagnosis. The use of GLP-1 injectables for weight loss has increased significantly, from 5.8% of adults in February 2024 to 12.4% in 2025.
Age Groups and Obesity Reduction
The report found that the biggest reduction in obesity was among those aged 40 to 49 and those aged 50 to 64. These age groups also have the highest rates of GLP-1 injectables for weight loss. The trend suggests that the increased use of these medications may be contributing to the decline in obesity rates. However, the report notes that the method of collecting self-reported weight and height data may introduce some bias, although the consistent collection method provides valuable information on changes over time.
Despite the decline in obesity rates, the US still exceeds many Western countries in terms of weight. According to data from the Centers for Disease Control and Prevention, around 40% of adults in the US are obese. However, the expansion of access to weight loss treatments may be a factor in the obesity decline becoming a lasting trend. The report’s findings are consistent with reports of steadily increasing use of GLP-1 injectables since their initial FDA approval in 2021.
Conclusion and Further Reading
The decline in US obesity rates is a positive trend, and the increased use of weight loss medications like GLP-1 injectables may be a contributing factor. For more information on this topic, visit Here to read the full article and explore related resources.
Image Source: www.cbsnews.com
